PE20120020A1 - Composicion farmaceutica que comprende un profarmaco inhibidor de la polimerasa de vhc - Google Patents
Composicion farmaceutica que comprende un profarmaco inhibidor de la polimerasa de vhcInfo
- Publication number
- PE20120020A1 PE20120020A1 PE2011001307A PE2011001307A PE20120020A1 PE 20120020 A1 PE20120020 A1 PE 20120020A1 PE 2011001307 A PE2011001307 A PE 2011001307A PE 2011001307 A PE2011001307 A PE 2011001307A PE 20120020 A1 PE20120020 A1 PE 20120020A1
- Authority
- PE
- Peru
- Prior art keywords
- amount
- pharmaceutical composition
- composition including
- drug
- polymerase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTIICA QUE COMPRENDE: A) UN INHIBIDOR DE LA POLIMERASA DEL VIRUS DE LA HEPATITIS C QUE ES EL (2R,3R,4R,5R)-5-(4-AMINO-2-OXO-2H-PIRIMIDIN-1-IL)-4-FLUORO-2-ISOBUTIRILOXIMETIL-4-METIL-TETRAHIDRO-FURAN-3-IL ESTER DE ACIDO ISOBUTIRICO EN UNA CANTIDAD DE 50% A 95% p/p; B) HIDROXIPROPILCELULOSA EN UNA CANTIDAD DE 1% A 4% p/p; C) UN ADYUVANTE DE COMPRESION TAL COMO LACTOSA MONOHIDRATO, CELULOSA MICROCRISTALINA, ENTRE OTROS; D) UN DESINTEGRANTE TAL COMO CROSCARMELOSA SODICA, CROSPOVIDONA, ENTRE OTROS, EN UNA CANTIDAD DE HASTA 10% p/p; E) UN GLIDANTE TAL COMO TALCO, DIOXIDO DE SILICIO COLOIDAL, ENTRE OTROS, EN UNA CANTIDAD DE HASTA 5% p/p; F) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO, ACIDO ESTEARICO, ENTRE OTROS, EN UNA CANTIDAD DE HASTA 2% p/p; G) UN AGENTE DE RECUBRIMIENTO DE PELICULA TAL COMO HIPROMELOSA O ALCOHOL POLIVINILICO DE DIOXIDO DE TITANIO Y TALCO, ENTRE OTROS, EN UNA CANTIDAD DE HASTA 5% p/p. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD MEDIADA POR EL VIRUS DE LA HEPATITIS C
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14599909P | 2009-01-21 | 2009-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120020A1 true PE20120020A1 (es) | 2012-02-02 |
Family
ID=42026386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001307A PE20120020A1 (es) | 2009-01-21 | 2010-01-11 | Composicion farmaceutica que comprende un profarmaco inhibidor de la polimerasa de vhc |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8222230B2 (es) |
| EP (1) | EP2389164B1 (es) |
| JP (1) | JP5415561B2 (es) |
| KR (1) | KR101331723B1 (es) |
| CN (1) | CN102292075B (es) |
| AR (1) | AR075037A1 (es) |
| AU (1) | AU2010206224B2 (es) |
| BR (1) | BRPI1006924A2 (es) |
| CA (1) | CA2748895C (es) |
| CL (1) | CL2011001764A1 (es) |
| CO (1) | CO6440558A2 (es) |
| DK (1) | DK2389164T3 (es) |
| EC (1) | ECSP11011191A (es) |
| ES (1) | ES2513415T3 (es) |
| HK (1) | HK1164742A1 (es) |
| IL (1) | IL213804A0 (es) |
| MA (1) | MA32969B1 (es) |
| MX (1) | MX2011007771A (es) |
| NZ (1) | NZ593795A (es) |
| PE (1) | PE20120020A1 (es) |
| PL (1) | PL2389164T3 (es) |
| RU (1) | RU2489153C2 (es) |
| SG (1) | SG173001A1 (es) |
| SI (1) | SI2389164T1 (es) |
| TW (1) | TWI414295B (es) |
| UA (1) | UA100937C2 (es) |
| WO (1) | WO2010084041A2 (es) |
| ZA (1) | ZA201104882B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012062691A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for treating hcv infections |
| EP2919903B1 (en) | 2012-11-14 | 2020-07-22 | W.R. Grace & CO. - CONN. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
| DE102013215831A1 (de) * | 2013-08-09 | 2015-02-12 | Beiersdorf Ag | Gelförmiges, alkoholisches Sonnenschutzmittel |
| WO2016121925A1 (ja) * | 2015-01-30 | 2016-08-04 | 協和発酵バイオ株式会社 | 機能性物質を高含有する錠剤及びその製造方法 |
| BR112018015370A2 (pt) * | 2016-02-19 | 2018-12-18 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica contendo derivado de imidazolina |
| JP6323846B2 (ja) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | オピオイドを含有する乱用防止製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1267446C (zh) * | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
| JP4408340B2 (ja) * | 2002-03-22 | 2010-02-03 | 武田薬品工業株式会社 | 速崩壊性固形製剤 |
| TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| KR20080027783A (ko) * | 2005-06-22 | 2008-03-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 난용성 활성 성분을 함유하는 정제 |
| JP2008230967A (ja) * | 2005-06-23 | 2008-10-02 | Kowa Co | 医薬組成物 |
| NZ568909A (en) * | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
| AU2006326130B2 (en) * | 2005-12-14 | 2011-09-22 | F. Hoffmann-La Roche Ag | HCV prodrug formulation |
-
2010
- 2010-01-11 CN CN2010800050195A patent/CN102292075B/zh not_active Expired - Fee Related
- 2010-01-11 JP JP2011546733A patent/JP5415561B2/ja not_active Expired - Fee Related
- 2010-01-11 PE PE2011001307A patent/PE20120020A1/es not_active Application Discontinuation
- 2010-01-11 WO PCT/EP2010/050182 patent/WO2010084041A2/en active Application Filing
- 2010-01-11 SI SI201030785T patent/SI2389164T1/sl unknown
- 2010-01-11 CA CA2748895A patent/CA2748895C/en not_active Expired - Fee Related
- 2010-01-11 NZ NZ593795A patent/NZ593795A/xx not_active IP Right Cessation
- 2010-01-11 UA UAA201110008A patent/UA100937C2/uk unknown
- 2010-01-11 KR KR1020117019277A patent/KR101331723B1/ko not_active IP Right Cessation
- 2010-01-11 PL PL10700233T patent/PL2389164T3/pl unknown
- 2010-01-11 EP EP10700233.9A patent/EP2389164B1/en active Active
- 2010-01-11 DK DK10700233.9T patent/DK2389164T3/da active
- 2010-01-11 RU RU2011134713/15A patent/RU2489153C2/ru not_active IP Right Cessation
- 2010-01-11 AU AU2010206224A patent/AU2010206224B2/en not_active Ceased
- 2010-01-11 BR BRPI1006924A patent/BRPI1006924A2/pt not_active IP Right Cessation
- 2010-01-11 MA MA34019A patent/MA32969B1/fr unknown
- 2010-01-11 SG SG2011051240A patent/SG173001A1/en unknown
- 2010-01-11 ES ES10700233.9T patent/ES2513415T3/es active Active
- 2010-01-11 MX MX2011007771A patent/MX2011007771A/es active IP Right Grant
- 2010-01-18 TW TW099101246A patent/TWI414295B/zh not_active IP Right Cessation
- 2010-01-18 US US12/689,004 patent/US8222230B2/en not_active Expired - Fee Related
- 2010-01-20 AR ARP100100124A patent/AR075037A1/es unknown
-
2011
- 2011-06-28 IL IL213804A patent/IL213804A0/en unknown
- 2011-06-30 CO CO11082167A patent/CO6440558A2/es not_active Application Discontinuation
- 2011-07-01 ZA ZA2011/04882A patent/ZA201104882B/en unknown
- 2011-07-07 EC EC2011011191A patent/ECSP11011191A/es unknown
- 2011-07-21 CL CL2011001764A patent/CL2011001764A1/es unknown
-
2012
- 2012-06-12 HK HK12105721.1A patent/HK1164742A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120020A1 (es) | Composicion farmaceutica que comprende un profarmaco inhibidor de la polimerasa de vhc | |
| ES2524771T3 (es) | Composiciones farmacéuticas que comprenden levetiracetam y procedimientos para su preparación | |
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| PE20130481A1 (es) | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona | |
| PE20090951A1 (es) | Suspension pediatrica estabilizada de carisbamato | |
| NZ597375A (en) | Tofa analogs useful in treating dermatological disorders or conditions | |
| EA029081B9 (ru) | Комбинированный состав двух противовирусных соединений | |
| RU2010128019A (ru) | Пероральная диспергируемая таблетка | |
| PE20121742A1 (es) | PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO | |
| WO2006099379A3 (en) | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors | |
| AR041089A1 (es) | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| PE20220751A1 (es) | Composiciones solidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico | |
| HRP20191939T1 (hr) | Postupci za liječenje hepatitisa c | |
| JP2018532806A5 (es) | ||
| MY149911A (en) | Methods for administering long-lasting hypoglycemic agents | |
| SI2895174T1 (en) | The prodrugs of the amino quinazoline kinase inhibitor | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| JP2016509051A5 (es) | ||
| AR073365A1 (es) | Preparacion farmaceutica solida de liberacion sostenida | |
| CL2008001678A1 (es) | Forma de dosificación farmacéutica de liberacion prolongada en forma de comprimido, que consiste de nevirapina anhidra, hipromelosa, lactosa monohidrato y estearato de magnesio; y su procedimiento de preparación, util para el tratamiento de una infeccion por vih-1. | |
| MY173873A (en) | Oral dosage forms of bendamustine | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |